Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2012 /
Advances in haemato-oncological treatment options

4th - 7th Nov 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.12
Views: 5366
Rating:

Prof Kenneth Anderson – Dana Farber Cancer Institute, Boston, UK

Prof Kenneth Anderson speaks to ecancer.tv about the substantial advances that have been made in the availability of haemato-oncological treatments.

 

Prof Anderson also outlines promising new research looking at the inhibition of proteasomes and aggresomes and discusses the importance of the patient microenvironment, the role this plays in cancer progression and the way that this can be targeted to improve treatment.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation